Krisstina Gowin, DO, University of Arizona Cancer Center

Harry P. Erba, MD, PhD, Duke Cancer Institute;Krisstina Gowin, DO, University of Arizona Cancer Center;Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center;Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center;Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center

July 7th 2020

Essential Thrombocythemia: Treatment Optimization

Harry P. Erba, MD, PhD, Duke Cancer Institute;Krisstina Gowin, DO, University of Arizona Cancer Center;Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center;Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center;Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center

July 7th 2020

Classifying Patients With Essential Thrombocythemia

Harry P. Erba, MD, PhD, Duke Cancer Institute;Krisstina Gowin, DO, University of Arizona Cancer Center;Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center;Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center;Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center

July 7th 2020

Primary Myelofibrosis: Trials of Interest

Harry P. Erba, MD, PhD, Duke Cancer Institute;Krisstina Gowin, DO, University of Arizona Cancer Center;Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center;Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center;Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center

July 7th 2020

JAK2 Inhibitor Selection for Primary Myelofibrosis

Harry P. Erba, MD, PhD, Duke Cancer Institute;Krisstina Gowin, DO, University of Arizona Cancer Center;Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center;Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center;Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center

July 7th 2020

Fedratinib for Primary Myelofibrosis

Harry P. Erba, MD, PhD, Duke Cancer Institute;Krisstina Gowin, DO, University of Arizona Cancer Center;Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center;Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center;Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center

July 7th 2020

Ruxolitinib and Surgical Interventions

Harry P. Erba, MD, PhD, Duke Cancer Institute;Krisstina Gowin, DO, University of Arizona Cancer Center;Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center;Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center;Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center

July 7th 2020

Ruxolitinib for Primary Myelofibrosis

Harry P. Erba, MD, PhD, Duke Cancer Institute;Krisstina Gowin, DO, University of Arizona Cancer Center;Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center;Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center;Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center

July 7th 2020

Treating Intermediate/High-Risk Primary Myelofibrosis

Harry P. Erba, MD, PhD, Duke Cancer Institute;Krisstina Gowin, DO, University of Arizona Cancer Center;Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center;Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center;Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center

July 7th 2020

Management of Low-Risk Primary Myelofibrosis

Harry P. Erba, MD, PhD, Duke Cancer Institute;Krisstina Gowin, DO, University of Arizona Cancer Center;Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center;Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center;Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center

July 7th 2020

Primary Myelofibrosis: Risk Stratification

Harry P. Erba, MD, PhD, Duke Cancer Institute;Krisstina Gowin, DO, University of Arizona Cancer Center;Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center;Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center;Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center

July 7th 2020

Polycythemia Vera: PROUD-PV Trial

Harry P. Erba, MD, PhD, Duke Cancer Institute;Krisstina Gowin, DO, University of Arizona Cancer Center;Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center;Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center;Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center

July 7th 2020

Utilization of Ruxolitinib for Polycythemia Vera

Harry P. Erba, MD, PhD, Duke Cancer Institute;Krisstina Gowin, DO, University of Arizona Cancer Center;Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center;Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center;Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center

July 7th 2020

Polycythemia Vera: Ruxolitinib Trial Data

Harry P. Erba, MD, PhD, Duke Cancer Institute;Krisstina Gowin, DO, University of Arizona Cancer Center;Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center;Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center;Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center

July 7th 2020

Polycythemia Vera: Switching Therapy

Harry P. Erba, MD, PhD, Duke Cancer Institute;Krisstina Gowin, DO, University of Arizona Cancer Center;Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center;Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center;Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center

July 7th 2020

Treatment Options for High-Risk Polycythemia Vera

Harry P. Erba, MD, PhD, Duke Cancer Institute;Krisstina Gowin, DO, University of Arizona Cancer Center;Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center;Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center;Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center

July 7th 2020

Management of Low-Risk Polycythemia Vera

Harry P. Erba, MD, PhD, Duke Cancer Institute;Krisstina Gowin, DO, University of Arizona Cancer Center;Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center;Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center;Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center

July 7th 2020

Polycythemia Vera: Monitoring Patients

Harry P. Erba, MD, PhD, Duke Cancer Institute;Krisstina Gowin, DO, University of Arizona Cancer Center;Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center;Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center;Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center

July 7th 2020

Polycythemia Vera: Risk Assessment

Harry P. Erba, MD, PhD, Duke Cancer Institute;Krisstina Gowin, DO, University of Arizona Cancer Center;Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center;Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center;Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center

July 7th 2020

Polycythemia Vera: Prognostic Markers

Harry P. Erba, MD, PhD, Duke Cancer Institute;Krisstina Gowin, DO, University of Arizona Cancer Center;Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center;Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center;Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center

July 7th 2020

Polycythemia Vera: Bone Marrow Biopsies

Harry P. Erba, MD, PhD, Duke Cancer Institute;Krisstina Gowin, DO, University of Arizona Cancer Center;Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center;Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center;Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center

July 7th 2020

Polycythemia Vera: Diagnostic Work-up

Harry P. Erba, MD, PhD, Duke Cancer Institute;Krisstina Gowin, DO, University of Arizona Cancer Center;Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center;Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center;Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center

July 7th 2020

Characterization of Myeloproliferative Neoplasms

Harry P. Erba, MD, PhD, Duke Cancer Institute;Krisstina Gowin, DO, University of Arizona Cancer Center;Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center;Jamile M. Shammo, MD, FASCP, FACP, Rush University Medical Center;Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center

July 7th 2020

The Cognitive Error Paradigm

Krisstina Gowin, DO, University of Arizona Cancer Center

August 15th 2014

As fellows in oncology, we are constantly required to assimilate data, interpret diagnostic tests, decide on appropriate treatment regimens, and employ compassionate care in an increasingly truncated allotment of time.

Lessons on Treating Cancer: A Caregiver's Perspective

Krisstina Gowin, DO, University of Arizona Cancer Center

September 13th 2013

Fighting cancer is much like fighting a war. As Sun Tzu states in Art of War, understanding yourself and the enemy will greatly increase the chance for victory.

Krisstina Gowin, DO, University of Arizona Cancer Center

Articles

Latest Updated Articles

Latest Conference Coverage